rethinkPeptides Search
Menu
Study breakdown

Opioid Peptide Met-Enkephalin Inhibits Cancer Cell Growth Through a Non-Classical Receptor

In VitroPreliminary evidence
The takeaway

Opioid growth factor (OGF/met-enkephalin) inhibited human pancreatic, colon, and squamous cell cancer proliferation through a novel nuclear receptor (OGFr) activating p16 and p21 cell cycle inhibitors — a distinct anti-cancer opioid mechanism.

Built-in tumor suppression

Met-enkephalin activates p16/p21 tumor suppressors through a nuclear receptor — the body has its own opioid-based cancer control system

What the researchers found

Met-enkephalin (OGF) inhibited cancer proliferation through OGFr nuclear translocation and activation of p16/p21 cell cycle inhibitors across pancreatic, colon, and squamous cell cancers — a non-classical opioid anti-cancer mechanism.

Why it matters

A natural opioid peptide that suppresses cancer through tumor suppressor activation represents an entirely new anti-cancer mechanism. It could be boosted to enhance natural tumor control.

How the study worked

In-vitro study using three human cancer cell lines. OGF binding, OGFr localization, p16/p21 induction, and cell cycle arrest measured. Classical opioid receptor involvement excluded with selective antagonists.

What this study cannot tell us

In-vitro cancer cell lines. The OGFr pathway's in-vivo significance and therapeutic potential need validation.

How to read the evidence

Preliminary in-vitro evidence across three cancer types with clear non-classical receptor identification and tumor suppressor activation.

When this study was published

Published in 2003. The OGF-OGFr pathway has been further characterized and is being explored for cancer therapy.

The bigger picture

The body has a built-in opioid-based tumor suppression system. Met-enkephalin naturally slows cancer growth through OGFr — boosting this system could be a novel cancer treatment strategy.

Questions still open

  • Could OGFr agonists be developed as cancer drugs?
  • Is the OGF-OGFr pathway deficient in cancer patients?
  • Would opioid drugs that block classical receptors inadvertently affect this anti-cancer pathway?

Common questions

Can the body's opioids fight cancer?
Yes — met-enkephalin (an endogenous opioid) naturally slows cancer growth. It works through a special nuclear receptor (not the regular pain receptors) that activates tumor suppressors to halt cancer cell division.
Could this be used for cancer treatment?
The OGF-OGFr pathway is being explored for cancer therapy. Boosting this natural system — or preventing its loss in cancer — could complement existing treatments.

Read the original research

Opioids and the apoptotic pathway in human cancer cells.

Neuropeptides, 37(2), 79-88

Citation

Zagon, Ian S; McLaughlin, Patricia J. (2003). Opioids and the apoptotic pathway in human cancer cells.. Neuropeptides, 37(2), 79-88.